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ABSTRACT 
The relationship between urinary dopamine levels, 
and arterial blood pressure was studied in male albino rats. 
The experimental rats were subjected to a right 
nephrectomy and received a monoamine oxidase inhibitor, 
either tranylcypromine or pargyline. 
The blood pressure of the group receiving tranyl-
cypromine was elevated to approximately 120 mm Hg during the 
first two weeks. During weeks seven and eight the blood 
pressure was further elevated to approximately 130 mm Hg but 
dropped back gradually to 115 mm Hg for a net drop of 3 per-
cent where it remained to the end of the study. The blood 
pressure of the pargyline group, as expected, dropped 
steadily from approximately 115 mm Hg to approximately 84 mm 
Hg for a net drop of 34 percent. 
Dopamine was extracted from paired urine samples by 
alumina and measured by spectrophotofluorimetry. Dopamine 
levels (mean from paired urine samples) of the experimental 
animals receiving pargyline or tranylcypromine were approx-
imately 6 ug/ml/24 hour urine sample and 5 ug/ml/24 hour 
urine sample. These were lower than the levels of the con-
trol groups. 
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I. IN TRODUCTION 
The catecholamines, epinephrine, norep in ephrine, and 
dopamine have at times been i mplicated i n pr oducing or 
maintaining hypertension. Of primary interest i n th i s 
study is 3-hydroxytyramine (dopamine), a precursor in the 
biosynthesis of norepinephrine and epinephrine; and mono-
amine oxidase (MAO), the enzyme which catalyzes the metabolic 
transformation of dopamine to norepinephrine. It was postu-
lated that if monoamine oxidase was inhibited, the result 
would be an increase of the ca techol am ines such as dopamine, 
in the body, and that this increase or accumulation of dop-
amine conceivably helps to maintain arterial hypertension. 
Goldblatt et .5!1· (1934) revealed that ischemia in the 
kidney~ produced an elevated systolic blood pressure. 
Ischemia in one kidney, while the other remains normal 
produces a temporary elevation of blood pressure about three 
or four days after the operation. However, if one kidney is 
removed and the artery of the ~emaining kidney constricted 
then permanent hypertension occurs. 
Defanti and Defeo (1963) have shown a possible 
relationship between blood pressure and urinary dopamine, 
and a correlation between increased urinary dopamine levels 
and a decreased monoamine oxidase activity. 
How, then could one of these catecholamines come to 
exist in excess in the body? Bing (1941) demonstrated that 
a presser substance, possibly dopamine, formed by decarboxyla-
tion of DOPA, occurred in extracts of guinea pig kidneys 
s 
, 
6. 
incubated under anerobic conditions. Schroede r (1942) showed 
that deamination but not decarboxylation of some amino acids 
is incomplete in kidneys deprived of their normal oxygen 
supply. Giordano et al. (1960) ~onfirmed the fi nding of 
Schroeder when he found a decrease in MAO activity in the 
kidneys of rabbits rendered hypertensive by renal ischemia. 
Defanti {1963) demonstrated a decrease in MAO activity in the 
kidneys of rats rendered hypertensive by renal ischemia. 
This study will attempt to demonstrate that when chem-
icals such as MAO inhibitors are administered to unilaterally 
nephrectomized rats in the absence of renal constriction, 
a rise in blood pressure and an increase in urinary dopamine 
occurs. The issue is approached by studying the relationship 
between arterial blood pressure and urinary dopamine levels 
in rats receiving a monoamine oxidase inhibi tor. 
II. REVIEW .Q.[ LITERATURE 
The disease hypertension has been known for centuries 
and has been actively studied for the past thirty years. It 
is of considerable interest that the etiology of the disease 
remains unknown to this day. 
The catecholamines epinephrine, norepinephrine and 
dopamine and the disease hypertension have long been 
associated with each other. The discovery that dopamine is 
a precursor in the biosynthesis of norepinephrine and 
epinephrine (Blaschke, 1957), and the discovery that mono-
amine oxidase is an enzyme primarily involved in the metabolic 
transformation of dopamine, has led to the investigation of 
the catecholamines and particularly dopamine as a possible 
factor in the cause and maintenance of arterial hypertension. 
The biochemical pathway of the formatidn of epinephrine 
is shown in figure 1. According to this accepted pathway, 
norepinephrine is the immediate precursor of epinephrine. It 
is clear then, that norepinephrine, a neurohormone in its own 
right is also an intermediate in epinephrine formation. The 
role of dopamine is not yet clearly understood as to whether 
it is a neurohormone as well as a precursor in the biosynthe-
sis of norepinephrine and epinephrine. The fact that dop-
amine disappears from brain tissue after administration of 
reserpine (Carlsson, .@..!:. ~. 1962) might give some indication 
of a functional role for dopamine. 
Studies of the circulatory effects of dopamine have 
been carried out in animals, but the results appear to differ 
with the species. Dopamine acts as a presser substance 
7 
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fig. 1. The enzymatic synthesis of norepinephrine and epinephrine. CJ> 
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when given intravenously in the cat (Holtz .§!. al. 1942) and 
also in the dog (Goldberg et ~· 1959) whereas in the guinea 
pig and rabbit it is a depressor substance (Holtz et~· 1951). 
It has recently been demonstrated that in the dog, 
dopamine is a depressor substance when administered in small 
doses but a presser substance when administered in larger 
doses (mcDonald et al. 1962). 
--
Although in 1951 Von Euler demonstrated the presence 
of dopamine in the urine of patients afflicted with phaeo-
chromocytoma, very few studies of the circulatory effects of 
dopamine have been carried out in man. (Horwitz, et ~· 1962) 
infused a 1 percent solution of dopamine in healthy subjects 
for up to thirty minutes and concluded that a dose of 5 to 
11 ug/kg/minute increased the systolic blood pressure, in-
creased the cardiac output and effected a change in the 
heart rate. To confirm the findings of Horwitz et al., 
Allwood and Ginsberg in 1962 infused dopamine at a rate of 
1 ug/minute and found a corresponding increase in systolic 
blood pressure up to two-hundred millimeters of mercury. 
The local effect of dopamine in the hand was also 
studied (Allwood et al. 1962). They concluded that since 
dopamine exerted different responses in the forearm, it 
therefore reacted with both alpha and beta receptors in the 
forearm vascular bed and that this preference was dependent 
upon the concentration of dopamine present. It is not known 
whether these peripheral vascular responses resulted from the 
direct effect of dopamine or whether dopamine is converted to 
another catecholamine. The peripheral vascular effects of 
dopamine in man is approximately one- f iftieth that of nor-
epinephrine when infused at a corresponding dose r ate. 
According to Horwitz et al. (1962) the effect of dopamine 
upon systolic blood pressure is evident with in two to four 
~inutes after starting the infusion. This is much longer 
than the time required for changes in systolic blood pressure 
to become evident with infusions of epinephrine or norepi-
nephrine. This slight delay (one minute) is probably 
caused by the rate of conversion of dopamine to norepinephrine 
in vivo, however, it appears since the effects of dopamine 
and norepinephrine are different, e.g. on heart rate, that the 
effects of dopamine upon heart rate are not dependent upon 
the formation of norepinephrine. Dopamine also differs from 
other catecholamines in another respect inasmuch as Allwood 
& Ginsberg (1962) described piloerection in the forearm 
during intra-arterial dopamine infusions. Other catechol-
amines cause piloerection in man when introduced intrader-
mall y but they do not when infused intra-arterially in 
physiological concentrations. As piloerection is part of 
an emotional or fright response in man, it has been suggested 
that the role of dopamine in the body is not solely as a 
precursor of norepinephrine. 
monoamine oxidase (mAO) and catechol-0-methylt r ans-
ferase (COmT) are of great importance in the metabolic 
transformation of epinephrine, norepinephrine and dopamine. 
mAO also oxidatively deaminates serotonin (5-HT). It ap-
pears that mAO metabolically transforms intracellular 
catecholamines while COMT metabolically transforms circu-
lating catecholamines. The enzyme MAO is located almost 
entirely in the mitochondrial fraction of cells. 
11. 
The intracellular concentration of dopamine differs 
from other catecholamines. The cytoplasm contains an abun-
dance of dopamine whereas much less is found in storage 
granules (Jarvik, m.E. 1964). Dopamine is also distributed 
differently in the CNS than other catecholamines. 
MAO inhibitors produce an irreversible inactivation 
of MAO by forming a stable inhibitor-enzyme complex (Jarvik, 
M.E. 1964). Since the synthesis of biogenic amines is not 
inhibited, and since MAO which limits the level of intra-
cellular amines is inhibited, amine concentration within 
the cell will increase. It is not known as yet to what 
extent the therapeutic action of MAO inhibitors is due to 
increases in intracellular concentration of biogenic amines. 
After administration of a single dose of a MAO in-
hibitor endogenous norepinephrin e , ep i nephrine, dopamine and 
5-HT levels increase in various tissues, including the heart, 
brain, and blood. MAO inhibi t ors also enhance the effect of 
exogenous amines such as 5-HT and norepinephrine, as well as 
their precursors, 3,4-dihydroxyphenylalanine (DOP A) or 5-hy-
droxytryptophan. These amino acids are capable of penetrating 
the blood-brain barrier and are decarboxylated in the brain 
to their correspondin g amines. In contrast to the precursors, 
these amines penetrate the barrier with difficulty. 
The degree to which MAO is inhibited in a particular 
organ of the body varies with the route of administration, 
the MAO inhibitor and the substrate used for determining the 
12. 
degree of inhibition (Zeller and Fouts, 1963). 
Tranylcypromine which is (Parnate R ) 1 was synthesized 
in 1948 as an amphetamine analog (Burger, A., and Yost, W.: J. 
Am. Chem. Soc. 1Qs2198, 1948). The structures for tranyl-
cypromine and amphetamine are shown in figure 2. 
I 
These agents are psychomotor stimulants and tranyl-
cypromine is used clinically in the treatment of psycho-
neurotic and psychotic depression. Tranylcypromine is also 
a potent inhibitor of MPO. The pharmacology of tranyl-
cypromine is rather scanty but it appears to resemble the 
pharmacology of the hydrazines; e.g. tranylcypromine elicits 
signs of CNS stimulation and sympathomimetic activity. 
Because tranylcypromine interferes with various enzymes such 
as MAO, it is able to prolong and intensify the action of 
other drugs and to interfere with steps in the metabolic 
pathways of several naturally occurring substances. 
It is believed that the action of sympathomimetic 
amines is potentiated following the administration of MAO 
inhibitors. This effect is mainly upon indirectly acting 
amines such as tyramine and amphetamine rather than upon 
directly acting amines (norepinephrine or epinephrine). 
Administered catecholamines are metabolically transformed by 
the enzyme COMT, hence, MAO inhibitors will have little or no 
effect upon prolonging and intensifying their action. However, 
certain sympathomimetic amines act peripherally, primarily 
by releasing catecholamine stores in nerve endings, and 
1. Registered tradename, Smith, Kline & French Laboratories, 
Philadelphia, Pennsylvania. 
13. 
0 -CH-CH-NH '\/ 2 c H 2 
TRANYLCYPROIYIINE 
AMPHETAMINE 
Fig. 2. Structures for tranylcypromine and amphetamine. 
14. 
since the level of amines is raised by MAO inhibitors pro-
found potentiation of effects such as presser action may be 
expected. 
III. INVESTIGATION 
A. OBJECTIVES 
The object of this investigation was to determine the 
effect of monoamine oxidase inhibitors upon urinary excretion 
of dopamine and to correlate this effect with changes in 
arterial blood pressure. 
The sp~cific objectives of this investigation werea 
1. To determine if there is a decrease in the 
biological metabolism of dopamine as evidenced by an increase 
in dopamine in the urine of male albino rats receiving a mono-
amine oxidase inhibitor and unilateral nephrectomy. 
2. To determine if the arterial blood pressure 
is elevated during this period and if there is a correlation 
between this elevated arterial blood pressure and the in-
creased urinary dopamine level. 
B. MATERIALS .Bl:!Q. METHODS 
1. General Considerations and Daily Protocol 
In this study rats were divided into six groups 
for daily intraperitoneal injection of either tranylcypromine, 
(Parnate R ) 1 , pargyline, (Eutonyl R ) 2 or the vehicle. 
Male, albino rats of the Sprague-Dawley strain 3 
weighing 90-100 g were distributed two to a cage in standard 
metabolism cage banks 4 and housed in a room maintained at 
22 ± 1 degree centigrade and approximately 50 percent relative 
1. Registered tradename of Smith, Kline & French Laborato-
ries, Philadelphia, Pennsylvania. 
2. Registered tradename of Abbott Laboratories, North 
Chicago, Illinois. 
3. Charles River Breeding Farms, North Wilmington, 
Massachusetts. 
4. Wahmann Mfg. Co., Baltimore, Maryland. 
15. 
humidity. The room was lighted by daylight t hrough two 
windows from sunrise to sunset. All studies except blood 
pressure determinations were carried out in this room. 
1 Each pair of animals was given 30 g of Purina rat 
16. 
chow daily at 5 PM. Fresh tap water was allowed ad libitum 
from .. two jars of approximately 250 ml capacity in each cage. 
Ail animals were weighed and injected daily from 9 AM to 1 Pm. 
Water jars, containers for the collection of urine and cages 
were cleaned and reset at this time. 
Drugs were prepared for intraperitoneal injection as 
followsa 500 mg of tranylcypromine sulfate was dissolved in 
sufficient glass distilled, de~ionized water to make 500 ml 
of solution to give a concentration of 1.0 mg/ml. 5000 mg 
of pargyline hydrochloride was dissolved in sufficient glass 
distilled, de-ionized water to make 500 ml of solution to 
give a concentration of 10.0 mg/ml. 
parts. 
Drug Doses .!!!!U:J! ~ followsa 
tranylcypromine sulfate 3. 3 mg/kg body weight 
pargyline hydrochloride 25 mg/kg body weight 
vehicle (glass distilled water) equal volume 
This investigation was carried out in two separate 
In Part 1a 74 animals were divided into six groups 
as follows and received the following treatmentsa 
Group I~ Unilateral nephr~ctomy and tranylcypromine 
1. Ralston Purina Co., St. Louis, Missouri. 
sulfate ~.3 . mg/kg of body weight. 
Group II1 Unilateral nephrectomy and pargyline 
hydrochloride, 25 mg/kg of body weight. 
17. 
Group III1 Unilateral nephrectomy and sham injection. 
Group IVs Sham operation on right kidney and tranyl-
cypromine sulfate, 3.3 mg/kg of body weight. 
Group Va Sham operation on right kidney and pargyline 
hydrochloride, 25 mg/kg of body weight. 
Group VI1 Sham operation on right kidney and vehicle. 
In addition, body weights, 24 hour urine sample and 
blood pressures were determined. 
In Part 2, 592 urine samples were assayed for 3-hydroxy-
tyramine (dopamine). The animals were sacrificed and the 
remaining kidney or kidneys removed and immediately frozen 
in liquid nitrogen for future analysis. 
A preliminary study involving four rats was under-
taken to determine gross toxicity effects of a daily in-
jection of 3.3 mg/kg of tranylcypromine sulfate. 
2. Preparation 2f. Unilaterally Nephrectomized ~ 
Male albino rats of the Sprague Dawley strain 1 weighing 
90-100 g were used for this study. To remove the right kidney, 
a dorsolateral incision approximately one-half inch in 
length was made midway along the spinal column on the dorsal 
side. The kidney was located retroperitoneal to the 
abdominal cavity and lateral to the incision. The kidney was 
forced up through the incision by manipulating it with the 
1. Charles River Breeding Farms, North Wilmington, Massachu-
setts. 
18. 
fingers and exposed for surgical removal. At this point the 
adrenal gland was stripped from the kidney and left intact. 
The renal artery and vein were then ligated with nylon 
thread, the kidney was removed and immediately frozen in 
liquid nitrogen for future analysis. 
The incision was closed with stainless steel wound 
clamps. Ether was the anesthetic used throughout the 
operation. 
3. Collection .Qf. Urine Sample 
The experimental rats were left for two weeks in a 
cage to recover and adjust to the nephrectomy. After the 
two week convalescent period, the animals were paired and 
placed in standard metabolism cages equipped with stainless 
steel funnels for collecting the urine. Urine collections 
were made three times weekly for the first few weeks then 
weekly for the remainder of the study. Twenty-four hour 
urine samples were collected in graduated cylinders contain-
ing 1.0 ml of 2.0 N sulfuric acid and immediately frozen at 
minus twenty degrees centigrade for future analysis. 
4. Determination .Qf. Blood Pressure 
All blood pressure studies were carried out in an 
Environtrol constant temperature chamber at 28 ± 1 degree 
centigrade which maintained low humidity by a rapid exchange 
of air within the chamber. To determine the blood pressure, 
the indirect systolic blood pressure tail-cuff method was 
employed. The rats were removed from their cages, placed 
19. 
into a plastic carrying cage, and heated in an incubator-
box equipped with two 25 watt electric bulbs which maintained 
the temperature in the incubator at approximately 40 ~ 2 
degrees centigrade. The rats were exposed to this tempera-
ture for approximately fifteen minutes. After warming, 
each rat was encased in a plastic chamber about 23 cm long by 
7 cm wide and 5 cm in height. The plastic holder is closed 
at one end, but by manipulating a movable piston, the 
internal length of the chamber was adjusted to fit each rat. 
The detachable partition was secured in place, leaving only 
the rat's tail exposed. 
An inflatable tail-cuff connected to a physiograph 
manometer system was placed around the base of the rat's 
tail. The tail was passed through a plastic holder 1 so 
designed that when the screwclamp arrangement was tightened, 
the tail was pressed into contact with a Beckman Infraton 2 
signal divider set to receive a maximum impulse. The In-
fraton output lead was plugged into the direct current in-
put of a Hewlett-Packard oscilloscope Model 1308 3 set at a 
sweep time of 20 msec/cm. 
With this system the systolic pressure pulsations in 
the rat's tail were converted to peaks on the oscilloscope 
screen. When the rubber bulb of the manometer system was 
manually squeezed, the pressure within the system increased, 
1. Constructed by Dr. John J. Defeo, Dept. of Pharmacology, 
University of Rhode Island. 
2. Beckman Co., Palo Alto, California. 
3. Hewlett-Packard Co., Palo Alto, California. 
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hence, the cuff became inflated and the peaks on the oscillo-
scope screen disappeared, as the circulation in the tail was 
depressed. The pressure within this system was regulated by 
opening the pressure escape valve on the manometer. As the 
circulation in the tail increased, the peaks reappeared upon 
the screen. When this occurred the systolic blood pressure 
was considered to be present because the pressure in the 
arteries is greater than the pressure in the manometer system. 
The rat blood pressure recorded on a particular day was 
the mean of at least three successive determinations not vary-
ing by more than approximately five mm of Hg. 
s. Preparation of Chromatographic Column 
Pyrex glass tubing approximately seven cm in length 
and one cm in diameter was drawn to a point approximately 
one-half cm in diameter. One end was fitted with a piece 
of polystyrene tubing approximately three cm in length 
attached to a funnel. A vinyl tube three cm long and one-
half cm in diameter conducted the eluate into a beaker. 
These glass columns permitted a flow rate of approximately 
fifteen drops per minute. 
6. Preparation .9..f. Aluminum Oxide 
One-hundred g of aluminum oxide 1 was washed with 500 
ml of 2.0 N hydrochloric acid for approximately twenty minutes 
at eighty degrees centigrade on a Temco controlled heat stir 
1. Aluminum Oxide for Chromatographic Adsorption 
Analysis, The British Drug Houses Ltd. B.D.H. 
Laboratory Chemical Division, Poole, England. 
Distributed in the U.S.A. by Gallard-Schlesenger Chemical 
Mfg. Corp., Carle Place~ L.I., N.Y. 
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plate. The alumina was then filtered through a sintered 
glass filter and washed again with 500 ml of hot 2.0 N 
hydrochloric acid. The alumina was suspended in glass dis-
tilled water and the supernatant liquid decanted carrying 
with it fine particles; about twenty seconds was allowed 
for the alumina to settle before decanting. This procedure 
was repeated ten times. The alumina was heated in an oven 
at one-hundred degrees centigrade until dry. 
7. Extraction of Catecholamines from Urine 
The urine sample was thawed and centrifuged for 
fifteen minutes. A 5 ml or 10 ml sample was transferred 
by volumetric pipet to a clean pyrex test tube. One to 
two drops of concentrated hydrochloric acid and 2 ml of 
D.25 M ethylenediaminetetracetic acid, di-sodium salt (EDTA) 
were added to the sample; the tubes were stoppered, heated 
in a water bath at one-hundred degrees centigrade for twenty 
minutes and cooled in a continuously flowing cold water bath. 
The sample was transferred with three 5 ml washings of glass 
distilled water to appropriate beakers. The pH of the 
sample was adjusted to 8.4 by titrating with 1 N sodium hy-
droxide; during the titration 1 ml of sodium bisulfite solu-
tion containing 10 mg/ml was added. The sample was then 
ready to be passed through a chromatographic column contain-
ing approximately 700 mg of acid washed alumina. 
8. Extraction of Dopamine from the Urine 
The pH of 700 mg of acid washed alumina in 10 ml of 
ammonium acetate buffer pH 8, was adjusted to a pH of 8.3 by 
adding 0.3 ml o~ five drops of 1 N sodium hydroxide. The 
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columns were packed and washed with five ml of glass dis-
tilled water. The above prepared urine sample was passed 
through the column, followed by 5 ml of 0.1 M sodium acetate, 
and 5 ml of glass distilled water. At this point the dop-
amine had been taken up by the alumina. Elution was accom-
plished with two consecutive 5 ml volumes of 0.2 N acetic 
acid which were collected in a clean dry beaker. 
9. Preparation .Qf. Eluate for Development 
A 3 ml aliquot of eluate was transferred to a clean 
calibrated pyrex tube. One ml each of 0.3 M potassium carbon-
ate and 0.1 M phosphate buffer pH 6.5, solution was added. 
10. Development of l fill Eluate 
Two drops of 0.25 M freshly prepared iodine solution 
was added to each tube containing the 3 ml eluate, phos-
phate buffer and potassium carbonate and mixed on a Vortex 
mixer allowing three minutes for completion of the iodine 
addition. After a total time of exactly three minutes from 
addition of iodine to the first tube, 1 ml of alkaline sul-
fite reagent was added and again mixed. Exactly four min-
utes from the addition of the alkaline sulfite solution, 
1 ml of 6 N acetic acid was added. All volumes were ad-
justed to 10 ml. These sample eluates were heated in a 
water bath at one-hundred degrees centigrade for five min-
utes, cooled and centrifuged for ten minutes . A sufficient 
quantity was poured into clean, clear fused quartz cells 
and irradiated for ten minutes under short wave ul tra-violet 
light . 
The fluorescence of the samples was read on an Aminco-
23. 
Bowman Spectrophotofluorometer. 1 The activation and fluores-
cent wavelengths were 325 mu and 380 mu (uncorrected instru-
ment values) respectively. 
A standard curve of known concentrations of dopamine 
was run with each set of samples assayed. Dopamine concen-
trations of 0.5 ug, 1.0 ug, 2.0 ug, and 3.0 ug respectively 
were used. These known dopamine concentration samples were 
treated experimentally as the urine samples with the exception 
of passing the urine samples through the alumina columns. 
With each group of urine samples, two samples of known 
dopamine concentration were assayed to ascertain per cent 
recovery. The known dopamine concentration samples were 
prepared by adding 2.0 ug of dopamine to 10 ml of distilled 
water and treated throughout the assay exactly as the urine 
samples. 
A linear relationship such as reported by Carlsson 
and Waldeck (1958) was found to exist between dopamine concen-
trations of 0.05 ug, 0.1 ug, 0.2 ug, 0.3 ug, 0.4 ug, and 0.5 
ug/ml and fluorescent intensity (figure 3). 
11. Weight ~Studies 
The effects of daily treatment with tranylcypromine, 
pargyline, unilateral nephrectomy and sham operation upon the 
daily body weights of each rat was determined. 
All animals were weighed daily prior to treatment, to 
the nearest gram on a Ohaus small animal balance 2 • Each 
rat was marked for identification and individual records were 
1. American Instrument Company, Inc., Silver Spring, Maryland. 
2. Ohaus Scale Corp., Union, New Jersey. 
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Fig. 3 Fluorescence intensity at varying concen-
trations of dopamine. 
Fluorescence is given in arbitrary units 
(meter multiplier value X % transmission 
x 1aa) 
Activating wavelength 325 mu ; fluorescent 
wavelength 38a mu. 
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TABLE 1 
Percent recovery a of dopamine added to samples. 
Total Dopamine Number 
Dopami.ne Added Calculated of 
ug/ml ug/ml Samples Percent Recovery 
2 1.46 51 73 
4 3.32 4 83 
6 4.95 4 82 
aAverage recovery equals seventy-nine percent. 
C. RESULTS 
All results, including values from the control group, 
values from the individual test groups, and statistical 
analyses are presented under this section. 
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1. Data for the Control Group are presented 1!l TABLE £. 
TABLE 2 
Control Group: Relationship of urinary dopamine levels (group mean) to arterial blood 
pressure (group mean) in male albino rats. 
Number 
Dopamine Dopamine Total Dopamine Blood Pressure of 
Week ug/ml/24hrs ug/kg ug/24hr sample mm Hg Animals 
1 0.5 .±. 0.1 a3.4 .±. 1a.3 15.2 .±. 3.0 108.5 .±. 2.1 14 
2 0.4 .±. 0.2 55.3 .±. 20.2 10.6 .±. 3.9 109.6 .±. l.a 14 
3 0.3 .±. 0.2 19.7 .±. 17.a 3.5 .±. 3.2 110.1 .±. 3.a 14 
4 0.6 .±. 0.2 96.0 .±. 47.2 21.9 .±. 11.4 112.3 .±. 3.9 14 
5 0.4 .±. 0.1 57.6 .±. 3a.6 10.6 .±. 2.3 1oa.9 .±. 3.2 14 
6 0.3 .±. 0.2 83.1 .±. 23.2 12.a .±. a.a 11a.5 .±. 3.6 14 
7 a.4 .±. a.5 96.7 .±. 53.2 1a.9 .±. 4.4 1aa.4 .±. 4.4 14 
a a.a .±. o.3 297.2 .±. 9a.9 22.3 .±. 11.5 1a9.o .±. 5.·6 14 
9 1.7 .±. a.3 143.6 .±. 114.4 67.4 .±. 19.3 104.2 .±. 9.7 14 
10 1.3 .±. D.6 39.9 .±. 28.6 37.8 .±. 31.1 104.4 .±. 4.4 14 
11 0.4 .±. 0.2 55.7 .±. 26.2 8.3 .±. 5.3 1a4.2 .±. 4.2 14 
12 a.3 .±. 0.1 29.7 .±. 17.a 13.9 .±. 6.2 1a6.5 .±. 2.7 14 
13 0.2 .±. a.1 28.6 .±. 5.2 7.0 .±. 3.8 1aa.5 .±. 3.a 14 
N 
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2. ~ !.Q.r. i!:l!!, Individual ~ Groups 1-s ~ presented 1o. !A-
bles 3-8. 
---
TABLE 3 
Relationship between urinary dopamine level and blood pressure in unilaterally nephrec-
tomized male albino rats receiving Parnate 3.3 mg/kg. 
Unilateral Number 
and Dopamine Dopamine Total Dopamine Blood Pressure of 
Parnate ug/ml/24hrs ug/kg ug/24hr sample mm Hg animals 
1 D.4 .±. D.1 55.0 .:!:. 27.1 12.3 .:!:. 6.1 122.1 .:!:. 9.0 12 
2 0.2 .±. 0.1 31.9 .±. 12.3 5.0 .±. 1.7 123.9 .±. 10.6 12 
3 0.2 .±. 0.1 23.0 .±. 10.8 4.9 .±. 2.3 116.8 .t. 7.5 12 
4 0.3 .t. 0.1 27.0 .t. 15.7 5.8 .±. 3.3 114.0 .±. 10.8 12 
5 0.3 .±. D.2 48.0 .t. 15.6 4.2 .±. 3.4 109.5 .t. 6.4 12 
6 D.4 .t. D.1 23.9 .±. 14.1 9.5 .±. 3.3 125.1 .±. 10.0 12 
7 0.2 .±. 0.1 15.1 .±. 15.6 5.1 .±. 3.o 131.8 .±. 6.6 12 
8 0.2 .±. 0.1 20.4 .±. 10.0 3.2 .±. 3.3 128.1 .±. 6.3 12 
9 0.2 .±. 0.1 17.7 .±. 15.8 4.3 .±. 2.1 118.7 .±. 6.6 12 
10 D.3 .±. D.2 14.5 .±. 3.2 4.0 .±. 3.4 107.8 .t. 8.3 12 
11 0.2 .±. 0.1 14.6 .± 6.4 3.2 .±. a.a 116.4 .±. 11.4 12 
12 0.2 .±. 0.1 38.9 .±. 35.6 9.1 .±. a.6 115.0 .t. 6.1 12 
"' ID
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TABLE 4 
Relationship between urinary dopamine level and blood pressure in unilaterally nephrec-
tomized male albino rats receiving Pargyline 25 mg/kg. 
Unilateral Number 
and Dopamine Dopamine Total Dopamine Blood Pressure of 
Pargyline ug/ml/24hrs ug/kg uq/24hr sample mm Hg animals 
1 0.2 .:I:. 0.2 21.3 .:I:. 22.3 4.6 .±. 4.8 116.2 .:I:. 11.0 16 
2 0.3 .±. 0.1 32.6 .±. 18.6 6.5 .±. 3.7 129.1 .±. 8.9 16 
3 0.7 .:I:. 0.4 52.4 .:I:. 35.2 11.1 .±. 7.6 123.3 .:I:. 10.0 16 
4 0.4 .:I:. 0.2 27.2 .±. 17.9 5.9 .:I:. 4.1 124.7 .±. 15.4 15 
5 0.2 .±. 0.1 59.1 .:I:. 41.9 2.6 .:I:. 1.1 103.9 .:I:. 10.7 16 
6 0.7 .:I:. 0.2 21.2 .:I:. 8.9 11.5 .:I:. 7.5 104.5 .±. 12.7 16 
7 0.3 .±. 0.1 13.3 .:I:. 6.5 4.6 .:I:. 1.9 105.1 .:I:. 17.0 15 
8 0.2 .±. 0.1 3.8 .±. 6.1 2.7 .:I:. 1.3 98.0 .:I:. 13.1 15 
9 0.2 .:I:. 0.1 61.8 .:1:. 43.6 0.9 .:I:. 1.3 92.8 .±. 10.2 15 
10 0.7 .±. 0.3 34.1 .:I:. 27.9 16.2 .:I:. 9.8 91.2 .±. 6.2 15 
11 0.4 .:I:. 0.3 29.3 .:I:. 21.9 7.5 .:I:. 6.0 106.8 ±. 9.0 15 
12 0.4 ±. 0.2 7.4 .:I:. 14.9 6.2 .:1:. · 4.8 99.6 .:I:. 13.0 13 
~ 
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TABLE 5 
Relationship between urinary dopamine level and blood pressure in unilaterally 
nephrectomized male albino rats receiving sham injection. 
-- --------- - -···-----· 
Dopamine Dopamine Total Dopamine Blood Pressure 
Unilateral ug/ml/24hrs ug/kq ug/24hr sample mm Hg animals 
1 0.2 .±. 0.1 33.7 .t. 10.3 6.1 .t. 3.6 119.1 .t. 11.7 10 
2 0.5 .t. 0.1 29.2 .t. 17.3 16.3 .±. 6.3 123.5 .t. 9.8 10 
3 0.6 .t. 0.4 75.8 .t. 31.9 7.3 .t. 5.0 124.6 .t. 8.7 10 
4 0.6 .:t. 0.1 29.9 .t. 20.0 18.2 .t. 3.7 122.2 .±. 10.5 10 
5 0.6 .t. 0.1 72.7 .t. 11.2 9.1 .t. 2.5 122.2 .t. 4.5 10 
6 0.8 .t. 0.3 86.6 .t. 53.4 21.0 .t. 12.s 125.5 .t. 4.9 10 
7 0.7 .t. 0.4 43.5 .±. 27.0 11.0 .±. 6.7 120.9 .±. 6.4 10 
8 0.3 .t. 0.1 20.8 .±. 11.2 5.1 .t. 2.8 111.5 .t. 7.0 10 
9 0.2 .±. 0.1 8.1 .±. 7.1 2.0 .±. 1.7 106.5 .±. 4.5 10 
10 0.2 .±. 0.1 12.6 .t. 7.8 3.5 .±. 2.2 106.1 .±. 3.8 10 
11 0.2 .t. 0.1 27.0 .±. 31.2 6.9 .±. a.a 111.4 .±. 13.1 10 
12 0.4 .±. 0.1 34.3 .t. 13.3 B.7 .t. 3.3 110.9 .t. 6.4 10 
~ 
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TABLE 6 
Relationship between urinary dopamine level and blood pressure in sham operated male 
albino rats receiving Parnate 3.3 mg/kg. 
Sham Number 
and Dopamine Dopamine Total Dopamine Blood Pressure of 
Parnate ug/ml/24hrs ug/kg ug/24hr sample mm Hg animals 
1 0.3 .:t. 0.2 30.7 .±. 21.6 6.3 .:t. 4.2 123.1 .:t. 7.9 14 
2 0.2 .:t. 0.1 28.9 .:t. 11.3 5.2 .:t. 1.9 125.0 .:t. 7.0 14 
3 0.6 .±. 0.5 54.2 .t. 43.7 11.4 .t. 9.5 133.2 .±. 7.3 14 
4 0.6 .t. 0.2 59.7 .t. 29.1 13.1 .:t. 6.3 104.4 .:t. 8.2 14 
5 0.3 .:t. 0.2 53.3 .t. 24.7 6.6 .±. 1.9 136.4 .t. 6.1 14 
6 0.5 .:t. 0.3 32.4 .t. 27.6 11.2 .±. 5.4 110.5 .±. 8.9 14 
7 0.4 .t. 0.3 58.6 .t. 59.5 7.2 .t. 6.1 106.7 .t. 7.4 14 
8 0.7 .t. 0.6 40.4 .t. 27.4 12.1.t.12.1 104.7 .±. 3.1 14 
9 0.5 .t. 0.2 26.2 .t. 16.7 8.9 .±. 6.2 105.0 .t. 4.0 14 
10 0.6 .:t. 0.4 30.5 .t. 9.5 6.9 .t. 4.7 103.1 .t. 9.8 14 
11 0.3 .t. 0.1 24.6 .t. 13.6 7.2 .±. 2.2 104.4 .t. 8.6 14 
12 0.2 .t. 0.1 95.9 ± 45.5 5.4 ± 2.9 106.4 .± 6.0 14 
~ 
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TABLE 7 
Relationship between urinary dopamine level and blood pressure in sham operated male 
albino rats receiving Pargyline 25 mg/kg. 
Sham Number 
and Dopamine Dopamine Total Dopamine Blood Pressure of 
Pargyline ug/ml/24hrs ug/kg ug/24hr sample mm Hg animals 
1 D.5 .:t. 0.1 37.6 .:t. 18.D 8.6 .±. 4.2 117.5 .:t. 7.0 12 
2 0.4 .±. 0.2 61.1 .±. 40.6 12.0 .±. 8.3 110.0 .±. 6.4 12 
3 0. 5 .±. 0.1 72.2 .:t. 31.1 15.7 .±. 6.3 105.5 ±. 6.2 12 
4 0.9 .±. 0.5 136.4 .:t. 81.6 30.9 .±. 18.3 99.5 .±. 5.7 12 
5 0.8 .±. 0.1 141.8 .±. 34.4 14.6 .±. 2.0 100.4 .±. 6.2 12 
6 1.1 .±. 0.2 53.5 .±. 35.1 32.9 ±. 7.4 98.8 .±. 4.6 12 
7 0 . 5 .±. 0.3 53.7 .±. 28.0 12.7 .±. 8.1 96. 5 ± 4.9 12 
8 0 .6 .±. 0.2 138.6 .±. 56.0 12.1 .±. 6.4 95.0 .±. 5.8 12 
9 1.1 .±. 0.6 144.9 .±. 88.8 30.4 .±. 12.3 96.4 .±. 9.7 12 
10 1.6 ±. o.s 80.1 .±. 22.6 35.7 .±. 23.5 102.2 .±. 9.6 12 
11 1.1 .±. 0.3 32.7 .±. 21. 7 19.1 .±. 5.5 83.5 .±. 10.1 12 
12 0 .3 .±. 0 . 2 101.2 .± 49 . 4 7.2 .±. 4 .9 72.8 .±. 7.7 12 
(.N 
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TABLE 8 
Relationship between urinary dopamine level and blood pressure in sham operated male 
albino rats receiving Solvent. 
Sham Number 
and O.opE).mi.ne Dopamine Total Dopamine Blo.od Pre.ssure of 
Solvent ug/ml/24hrs ug/kg ug/24hr sampl e mm Hg animals 
1 0.5 .±. 0.1 83.4 .±. 18.3 15.2 .±. 3.0 108.5 .±. 2.1 10 
2 0.4 .±. 0.2 55.3 .±. 20.2 10.6 .±. 3.9 109.6 .±. 1.8 10 
3 0.3 .±. 0.2 19.7 .±. 17.8 3.5 .±. 3.2 110.1 .±. 3.8 10 
4 0.6 .±. 0.2 96.0 .±. 47.2 21.9 .±. 11.4 112.3 .±. 3.9 10 
5 0.4 .±. 0.1 57.6 .±. 38.6 10.6 .±. 2.3 108.9 .±. 3.2 10 
6 0.3 .±. 0.2 83.1 .±. 23.2 12.0 .±. a.a 110.5 .±. 3.6 10 
7 o.6 .±. o.5 96.7 .±. 53.2 18.9 .±. 4.6 108.4 .±. 4.4 9 
8 a.a.±. o.3 287.2 .±. 90.9 22.3 .:t 11.s 109.0 .:t 5.6 9 
9 1.7 .:t 0.3 143.6 .:t 28.6 67.4 .:t 19.3 104.2 .±. 9.7 9 
10 1.3 .:t 0.6 55.7 .:t 26.2 37.8 .:t 31.1 107.4 .:t 4.6 9 
11 0.4 .:t 0.2 29.7 .:t 17.0 8.3 .:t 5.3 104.2 .:t 4.2 9 
12 0.3 .:t 0.1 28.6 .:t s.2 13.9 .:t 6.2 106.5 .±. 2.7 9 
~ 
~ 
• 
35. 
3. Pooled Data from all Individual Test Groups are presented in 
TABLE 9 and FIGURES 4-18. 
TABLE 9 
IYlaster Tablet Relationship between urinary dopamine levels and arterial blood pressure 
of individual groups. 
Nljmber 
Dopamine . Dopamine Total Dopamine Blood Pressure of 
Group LUeeks ug/ml/24hrs ug/kq uq/24hr sample mm Hg animals 
Sham + Solvent 12 0.6 .:I:. 0.4 86.2 .:I:. 63.8 19.2 .:I:. 16.4 108.3 .:I:. 2.4 14 
Unilateral + 12 0.4 .:I:. 0.2 36.7 .:I:. 27.5 8.9 .:I:. 5.9 115.2 .:I:. 7.2 10 
Sham Injection 
Unilateral + 12 0.3 .:I:. 0.1 26.4 .:I:. 10.6 5. 7 .:I:. 2.7 104.5 .:I:. 14.6 11 
Parnate 
Unilateral + 12 D.3 .:I:. 0.2 28.3 .:I:. 18.3 6.2 .:I:. 4.2 111.9 .:I:. 12.9 11 
Pargyline 
Sham + Parnate 12 o.s .:I:. 0.2 44.6 .:I:. 21.9 9.5 .:I:. 4.5 110.0 .:I:. 11.4 14 
Sham + 
Pargyline 12 0.8 .:I:. D.3 84.8 .:I:. 42.4 19.7 .:I:. 10.0 97.7 .:I:. 11.B 12 
All values represent means with standard deviations of six groups of male albino rats for 
the length of time specified in column two. 
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IV. DISCUSSION 
Blood Pressure Studies. 
52. 
The indirect tail-cuff method employed for deter-
mining arterial blood pressure of male albino rats was found 
to be satisfactory. The blood pressure of the experimental 
rats receiving tranylcypromine was elevated to 134 mm Hg dur-
ing the sixth week but at the end of the twelfth week the 
blood pressure had dropped to 115 mm Hg for a net drop of 
approximately three percent. The blood pressure of the exper-
imental group receiving pargyline dropped from a high of 
128 mm Hg to 84 mm Hg for a net drop of approximately thirty-
four percent. The mean blood pressure of the control group 
receiving a sham operation and the solvent was 108 mm Hg and 
remained at that level to the end of the investigation. At 
no time during the study did the blood pressure of this group 
deviate more than 9 mm Hg during any week . 
In comparing the various groups by using the Student's 
t-test for a test of significance at the 95 percent level, 
it was found that any change in arterial blood pressure was 
the result of the drug, either tranylcypromine or pargyline. 
It was noted that after twelve weeks of treatment, the exper-
imental rat group receiving pargyline could not tolerate the 
slightest stress such as pre-heating in the incubator prior 
to determining the blood pressure. This stress caused some 
of them to succumb to suffocation. This unusual sensitivity 
to stress can probably be explained on the basis of pargyline 
induced hyperthermia. The experimental rats receiving tranyl-
cypromine were also susceptible to this stress but seemed to 
53. 
tolerate it better than the experimental rats receiving 
pargyline. Although tranylcypromine also can induce hyper-
thermia, the hyperthermic effect at a dose of 3.3 mg/kg was 
not euf f icient to cause rapid suffocation and death. 
Dopamine Studies. 
A modification of the Carlsson & Waldeck (1958) 
method for determining urinary dopamine was found to be 
satisfactory. Dopamine concentrations of 2 ug, 4 ug, and 
6 ug/ml were added to samples and extracted on chromato-
graphic columns containing 700 mg of acid washed alumina. 
Percent recoveries of dopamine added to samples was seventy-
nine percent. A linear relationship was found to exist be-
tween dopamine concentrations of 0.1 ug to 0.4 ug/ml as re-
ported by Carlsson~ .!l.• (1958). Dopamine concentrations 
were reported in ug/ml/24 hour urine sample, total dopamine 
in ug/24 hour urine sample and in ug/kg of body weight. In 
all instances urinary dopamine was assayed from paired rat 
urine samples. The dopamine, ug/kg of body weight of the 
sham operated rat group receiving the solvent and the sham 
operated group receiving pargyline was nearly the same, how-
ever, the blood pressure of the group receiving pargyline was 
approximately 13 mm Hg lower. This was expected since 
pargyline has been reported to lower blood pressure experimen-
tally in rats, Deranti & Defeo (1962). 
The two enzymes responsible for the metabolic trans-
formation of dopamine in the body are catechol-0-methyl-
transferase (COMT), Axelrod, J., (1957) and monoamine oxidase 
54. 
(MAO), Blaschke, H., (1957). ·Dopamine may be methylated 
directly by the enzyme COMT or deaminated by the enzyme MAO. 
The preferential route for the metabolic transformation seems 
to be oxidative deamination via the enzyme MAO; however, the 
administration of dopamine to rats results in excretion of 3-
methoxytyramine both free and conjugated, Axelrod, J., JU.!,!., 
(1958). In contrast to epinephrine and norepinephrine, the 
methoxylation of dopamine occurred only to a minor extent, 
and considerable quantities of homovanillic acid, a deaminated 
metabolite of 3-methoxytyramine were found in the rat urine. 
This might lead one to search for other metabolites of dop-
amine in the urine instead of a free or conjugated form. 
An attempt to compare the two variables, using a simple 
regression method proved unsatisfactory. According to the 
data obtained from this study no linearity exists between 
arterial blood pressure and urinary dopamine. 
Results from this investigation indicate that the blood 
pressure in experimental male albino rats receiving the MAO 
inhibitors tranylcypromine or pargyline is not elevated, nor 
is the urinary dopamine level increased. further investigation 
into the alternate pathways of the metabolic transformation 
of dopamine and assaying for metabolites of dopamine must be 
conducted before one can fully conclude whether there is a 
correlation between arterial blood pressure and urinary 
dopamine. 
55. 
v. summARY ~ CONCLUSIONS 
This study investigated the interrelationship between 
arterial blood pressure and urinary dopamine levels in male 
albino rats receiving a monoamine oxidase inhibitor and a 
unilateral nephrectomy. 
1. The arterial blood pressure of the experimental 
rats receiving a monoamine oxidase inhibitor and a unilateral 
nephrectomy was not elevated. The blood pressure of the 
groups receiving a MAO inhibitor and a unilateral nephrectomy 
reached a high of approximately 135 mm Hg during the sixth 
week but gradually dropped to approximately 85 mm Hg. 
A modificateion of the dopamine bioassay of Carlsson 
& Waldeck, (1958) was used to determine dopamine quantitatively 
and proved satisfactory. Dopamine was extracted from paired 
urine samples by chromatographic alumina columns and measured 
by spectrofluorimetric methods. This method proved satis-
factory with average recovery for dopamine being seventy-nine 
percent. 
2. The urinary dopamine levels of the experimental 
groups were based upon ug of dopamine/kg of body weight and 
were found to be lower than the control group. 
3~ Based upon the method and design of this investi-
gation and applying the data obtained, no linear correlation 
exists between the two variables blood pressure and dopamine. 
Applying the data to test the goodness of fit it was found 
that no linearity existed between blood pressure and urinary 
dopamine. 
56. 
4. No definite relationship between blood pressure and 
urinary dopamine was established. Dopamine levels of the 
experimental rats did not rise nor was the blood pressure 
elevated. further investigation into the relationship between 
arterial blood pressure and dopamine is needed before a clear 
r elationship can be established between arterial blood pressure 
and urinary dopamine. 
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